Notify Therapeutics

Executive Summary

Notify Therapeutics is a Danish biotech company founded in 2019, pioneering a first-in-class, non-hormonal approach to treat female infertility. The company addresses a significant unmet need for women with diminished ovarian reserve (DOR) who are poor responders to conventional hormone therapies. By stimulating the initial, hormone-independent phase of ovarian follicle development, Notify aims to generate quality eggs and improve fertility outcomes without the side effects of hormonal stimulation. This innovative mechanism targets the earliest stages of folliculogenesis, potentially enabling a broader population of women to benefit from assisted reproductive technologies. The company is privately held and based in Copenhagen, Denmark. Notify's platform has the potential to disrupt the $25 billion fertility market by offering a safer and more effective option for DOR patients. While still in preclinical stages, the company's science is supported by strong academic foundations and has garnered interest from investors and partners. Key upcoming milestones include the completion of preclinical proof-of-concept studies, an IND-enabling toxicology program, and a potential Series A financing round. If successful, Notify could become a leader in non-hormonal fertility therapeutics, addressing a critical gap in reproductive medicine.

Upcoming Catalysts (preview)

• Q1 2027Preclinical proof-of-concept data in animal models35% success
• Q3 2027IND-enabling studies initiation or completion30% success
• 2026-2027Series A financing or partnership announcement40% success